URGN Urogen Pharma

UroGen Pharma to Report Second Quarter 2018 Financial Results on Tuesday, August 14, 2018

UroGen Pharma to Report Second Quarter 2018 Financial Results on Tuesday, August 14, 2018

Conference Call and Webcast Scheduled for 8:30 AM ET

RA’ANANA, Israel and NEW YORK, Aug. 07, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN) today announced that it will report second quarter 2018 financial results on Tuesday, August 14, 2018, prior to the open of the market. The announcement will be followed by a live audio webcast and conference call at 8:30AM Eastern Time.

Audio Webcast

The webcast will be made available on the Investors section of the Company’s website at . Following the live audio webcast, a replay will be available on the Company's website for approximately two weeks.

Dial-In Information

Live (U.S. / Canada): 1 (888) 771-4371

Live (International): 1 (847) 585-4405

Confirmation number: 47260983

About UroGen Pharma Ltd.

UroGen Pharma Ltd. (Nasdaq:URGN) is a clinical-stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology. UroGen has developed RTGel™, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s lead product candidates, UGN-101 (MitoGel®) and UGN-102 (VesiGel™), are designed to potentially remove tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma and bladder cancer, respectively. UroGen is headquartered in Ra’anana, Israel with U.S. headquarters in New York.

UROGEN CONTACT:

Kate Bechtold

Director, Corporate Communications & Investor Relations



914-552-0456  

EN
07/08/2018

Underlying

URGNUrogen Pharma

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Urogen Pharma

 PRESS RELEASE
Free
URGN UROGEN PHARMA

UroGen Announces ZUSDURI™ Launch is On-Track and Reports Fourth Quarte...

UroGen Announces ZUSDURI™ Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results Commercial launch is on-track for ZUSDURI™, the first and only FDA-approved medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC); net sales in 2025 were $15.8 million, reflecting the initial launch period ahead of the permanent J CodePermanent J Code for ZUSDURI became effective on January 1, 2026, streamlining reimbursement procedures and supporting broader patient accessJELMYTO® achieved net product sales of $94 million i...

March 2, 2026 1 EN
 PRESS RELEASE
Free
URGN UROGEN PHARMA

UroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisor...

UroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisors Opportunistic refinancing meaningfully reduces cost of capital with 8.25% fixed interest rate and extends amortization period to Q1 2030 $200 million funded at closing to refinance the existing $125 million debt facility and provide additional non-dilutive capital Additional $50 million tranche available at Company’s discretion until June 30, 2027 PRINCETON, N.J., March 02, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that ...

March 2, 2026 1 EN
 PRESS RELEASE
Free
URGN UROGEN PHARMA

ZUSDURI™ Achieves Durable Complete Responses Across EORTC Risk Groups ...

ZUSDURI™ Achieves Durable Complete Responses Across EORTC Risk Groups in Patients with Recurrent LG-IR-NMIBC • EORTC Recurrence Score Analysis from the Pivotal ENVISION Trial to be Presented at the 2026 American Society of Clinical Oncology’s Genitourinary Cancers Symposium (ASCO-GU 2026) PRINCETON, N.J., Feb. 27, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative, non-surgical therapies for urothelial and specialty cancers, today announced new post-hoc analyses from the Phase 3 ENVISION trial showing that ...

February 27, 2026 1 EN
 PRESS RELEASE
Free
URGN UROGEN PHARMA

UroGen Pharma to Present at the TD Cowen 46th Annual Health Care Confe...

UroGen Pharma to Present at the TD Cowen 46th Annual Health Care Conference PRINCETON, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that management will present at the TD Cowen 46th Annual Health Care Conference to take place March 2-4, 2026. TD Cowen 46th Annual Health Care Conference Date / Time:March 3, 2026, at 1:50 PM ETFormat:Presentation and 1x1 investor meetingsLocation:Boston, MAWebcast Link: The webcast fro...

February 24, 2026 1 EN
 PRESS RELEASE
Free
URGN UROGEN PHARMA

UroGen Pharma to Report Fourth Quarter and Full-Year 2025 Financial Re...

UroGen Pharma to Report Fourth Quarter and Full-Year 2025 Financial Results on Monday, March 2, 2026 Conference Call and Webcast Scheduled for Monday, March 2, 2026 at 10:00 AM ET PRINCETON, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report fourth quarter and full-year 2025 financial results on Monday, March 2nd , 2026, prior to the open of the stock market. The announcement will be followed by a live...

February 23, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch